Patent ID: 8222272
Filing Date: 2012-07-17
Classification: A61K,A61P

Abstract:
1. A pharmaceutical formulation comprising: a. a solid dispersion of a macrolide compound of formula (I); and b. a non-dispersed, non-dissolved, crystalline form of the macrolide compound; wherein the amount of the solid dispersion of the macrolide compound is from about 50% to about 85% of the combined amount of the solid dispersion and the non-dispersed, non-dissolved crystalline form, wherein the combined amount equals 100% of a pharmaceutically acceptable amount, wherein the compound of formula (I) is represented by the following: wherein each vicinal pair of R a) represent two vicinal hydrogen atoms, or b) form a second bond between the vicinal carbon atoms to which they are attached; in addition to the meanings above, R R R X represents oxo group, (hydrogen atom, hydroxy group), (hydrogen atom, hydrogen atom) or —CH Y represents oxo group, (hydrogen atom, hydroxy group), (hydrogen atom, hydrogen atom) or N—NR R R R in addition R n is 1, 2 or 3; in addition to the meanings above, Y, R